JP7477177B2 - 毒性が低減されたハイブリッドアムホテリシンｂ誘導体 - Google Patents

毒性が低減されたハイブリッドアムホテリシンｂ誘導体 Download PDF

Info

Publication number
JP7477177B2
JP7477177B2 JP2021512448A JP2021512448A JP7477177B2 JP 7477177 B2 JP7477177 B2 JP 7477177B2 JP 2021512448 A JP2021512448 A JP 2021512448A JP 2021512448 A JP2021512448 A JP 2021512448A JP 7477177 B2 JP7477177 B2 JP 7477177B2
Authority
JP
Japan
Prior art keywords
alkyl
group
heterocyclyl
cycloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536462A (ja
JP2021536462A5 (enExample
Inventor
ディー バーク，マーティン
ヂャン，ジアバオ
カンデルウォル，アニュジ
サンタマリア，アナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2021536462A publication Critical patent/JP2021536462A/ja
Publication of JP2021536462A5 publication Critical patent/JP2021536462A5/ja
Application granted granted Critical
Publication of JP7477177B2 publication Critical patent/JP7477177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2021512448A 2018-09-07 2019-09-06 毒性が低減されたハイブリッドアムホテリシンｂ誘導体 Active JP7477177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728203P 2018-09-07 2018-09-07
US62/728,203 2018-09-07
PCT/US2019/049971 WO2020051465A1 (en) 2018-09-07 2019-09-06 Hybrid amphotericin b derivatives with reduced toxicity

Publications (3)

Publication Number Publication Date
JP2021536462A JP2021536462A (ja) 2021-12-27
JP2021536462A5 JP2021536462A5 (enExample) 2022-09-09
JP7477177B2 true JP7477177B2 (ja) 2024-05-01

Family

ID=69719049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512448A Active JP7477177B2 (ja) 2018-09-07 2019-09-06 毒性が低減されたハイブリッドアムホテリシンｂ誘導体

Country Status (8)

Country Link
US (1) US11198705B2 (enExample)
EP (1) EP3846823A4 (enExample)
JP (1) JP7477177B2 (enExample)
KR (1) KR102893040B1 (enExample)
CN (1) CN113056274A (enExample)
AU (1) AU2019335409B2 (enExample)
CA (1) CA3111565A1 (enExample)
WO (1) WO2020051465A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056274A (zh) 2018-09-07 2021-06-29 伊利诺伊大学评议会 具有降低的毒性的杂化两性霉素b衍生物
EP4009984A4 (en) * 2019-08-08 2023-09-06 The Board Of Trustees Of The University Of Illinois HYBRID AMPHOTERICIN B DERIVATIVES WITH REDUCED TOXICITY
AU2021325676A1 (en) * 2020-08-10 2023-03-30 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin B

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015190587A1 (ja) 2014-06-12 2015-12-17 塩野義製薬株式会社 ポリエンマクロライド誘導体
WO2016168568A1 (en) 2015-04-15 2016-10-20 Revolution Medicines, Inc. Derivatives of amphotericin b
WO2017100171A1 (en) 2015-12-08 2017-06-15 Kalyra Pharmaceuticals, Inc. Antifungal compounds and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102548341B1 (ko) * 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
JP6543272B2 (ja) 2014-05-16 2019-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 低減された毒性を有するアンホテリシンｂ誘導体
CN113056274A (zh) 2018-09-07 2021-06-29 伊利诺伊大学评议会 具有降低的毒性的杂化两性霉素b衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015190587A1 (ja) 2014-06-12 2015-12-17 塩野義製薬株式会社 ポリエンマクロライド誘導体
WO2016168568A1 (en) 2015-04-15 2016-10-20 Revolution Medicines, Inc. Derivatives of amphotericin b
WO2017100171A1 (en) 2015-12-08 2017-06-15 Kalyra Pharmaceuticals, Inc. Antifungal compounds and methods

Also Published As

Publication number Publication date
AU2019335409B2 (en) 2025-06-05
EP3846823A4 (en) 2022-04-20
EP3846823A1 (en) 2021-07-14
WO2020051465A1 (en) 2020-03-12
JP2021536462A (ja) 2021-12-27
US20200079811A1 (en) 2020-03-12
KR20210064247A (ko) 2021-06-02
US11198705B2 (en) 2021-12-14
CA3111565A1 (en) 2020-03-12
CN113056274A (zh) 2021-06-29
AU2019335409A1 (en) 2021-05-06
KR102893040B1 (ko) 2025-11-27

Similar Documents

Publication Publication Date Title
AU2019279928B2 (en) Amphotericin B derivatives with improved therapeutic index
JP7636004B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
JP7240811B2 (ja) アムホテリシンｂの誘導体
JP7656359B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
US11198705B2 (en) Hybrid Amphotericin B derivatives with reduced toxicity
JP6726192B2 (ja) アムホテリシンｂの尿素誘導体の簡便な合成法
US20230000891A1 (en) Hybrid amphotericin b derivatives with reduced toxicity
HK1244248B (en) Derivatives of amphotericin b

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240411

R150 Certificate of patent or registration of utility model

Ref document number: 7477177

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150